ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1226

Adherence With Current Osteoporosis Treatment Guidelines Among Rheumatologists Caring For Patients With Rheumatoid Arthritis Using Items From The Fracture Risk Assessment Tool Score

Jennifer Watt1, Andrew E. Thompson2, Nicole G. H. Le Riche3 and Janet E. Pope4, 1Medicine, University of Western Ontario, London, ON, Canada, 2Rheumatology, St. Josephs Health Ctr, London, ON, Canada, 3Department of Medicine, St. Joseph's Hospital, London, ON, Canada, 4Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: guidelines, osteoporosis, Rheumatoid arthritis (RA), risk assessment and steroids

  • Tweet
  • Email
  • Print
Session Information

Session Title: Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

To assess whether the Fracture Risk Assessment Tool (FRAX) score in patients with RA correlates with likelihood of osteoporosis (OP) prescription including drug treatment, calcium and vitamin D.

Methods:

Charts of serial RA outpatients (age>40 with a calculable BMI) were reviewed to determine the 10-year risk of major osteoporotic fracture with the FRAX. Use of calcium, vitamin D, OP treatment, and a patient’s BMD results were recorded. Odds ratios (OR) were calculated to determine if a higher FRAX score increased the likelihood of OP prescribing.

Results:

10-year risk of fracture was high in 92 (12.5%), moderate in 216 (29.3%), and low in 429 (58.2%). No patients had a FRAX score calculated in their records. Compared to those at low risk, patients identified as high risk were more likely to receive OP treatment (OR 16.31, 95% CI 9.45-28.13, p<0.0001); calcium (OR 3.89, 95% CI 2.43-6.25, p<0.0001); vitamin D (OR 3.46, 95% CI 2.12-5.64, p<0.0001); and have a BMD performed (OR 10.22, 95% CI 5.50-18.96, p<0.0001). Among 137 patients currently taking prednisone, 44.5% were prescribed a bisphosphonate. BMD tests were performed in 415 (56.3%), but only 228 were recorded on the specialists’ charts.

Conclusion:

Higher risk patients are more likely to have a BMD and receive treatment, as indicated by the clear dose response seen along the 10-year fracture risk from low to medium to high-risk groups. Although rheumatologists didn’t calculate the FRAX score, they recognize important clinical risk factors included in the FRAX tool.


Disclosure:

J. Watt,
None;

A. E. Thompson,
None;

N. G. H. Le Riche,
None;

J. E. Pope,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adherence-with-current-osteoporosis-treatment-guidelines-among-rheumatologists-caring-for-patients-with-rheumatoid-arthritis-using-items-from-the-fracture-risk-assessment-tool-score/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences